BIND, Rusnano portfolio company, completes IPO at NASDAQ

BIND Therapeutics, a biotech portfolio company of Rusnano, Russia?s nanotech giant, has completed an IPO at NASDAQ at $15 a share

Rusnano, Russia?s nanotech giant, announced last week that BIND Therapeutics, Inc., its biotech portfolio company, has completed an initial public offering (IPO) at NASDAQ. The company is reported to have floated 4,700,000 common shares at $15 per share. As a result, BIND Therapeutics has raised $70.5m. The company shares are now listed as ?BIND? at NASDAQ Global Select Market and were first traded at the U.S. exchange on September 20. BIND Therapeutics is Rusnano?s first portfolio company to have successfully completed an IPO in the American market...